News & Updates

May 1, 2017

Sage has been appointed by Vesselon based in Norwalk Connecticut USA. Vesselon uses patents from Columbia University on the use of microbubbles and ultrasound to improve the delivery and pharmacokinetics of cancer drugs to enhance their efficacy and improve their useful life from an IP point of view


Vesselon’s technologies for improved drug delivery and p...

December 20, 2016

Sage is representing Mateon Therapeutics, a US-based biopharma company focusing on Vascular Disrupting Agents (VDAs) for orphan oncology indications.

The company has two VDAs in clinical development, CA4P and OXi4503, the lead one of which is being studied in a phase 2/3 clinical trial in platinum resistant ovarian cancer.

Similar to anti-angiogenic agents...

November 28, 2016

Escend Therapeutics (www.escendpharma.com) is based in San Diego, CA, and develops small molecule therapeutics for oncology orphan drug indications. ES-3000 is an orally bioavailable small molecule (FW ~600 Da) with a unique mechanism of action and established clinical safety. ES-3000 ablates leukemic stem cells as it reduces β-catenin by inhibition of Ca...

September 2, 2016

ABOUT APR

Applied Pharma Research s.a. (www.apr.ch; “APR” or the “Company”) is a profitable, well-financed, privately held, Swiss developer of specialty healthcare products, with over 20 years of experience. APR has a proven track record in successfully developing and marketing novel products in various therapeutic areas on a global basis. APR identifies,...

August 25, 2016

Solasia has engaged The Sage Group to manage a program to establish a global partnership regarding licensing of its Darinaparsin product in USA and Europe.

Darinaparsin or SP-02 is a new product from Solasia for the treatment of Peripheral T-Cell Lymphoma (PTCL). Solasia is working with Sage Group to license SP-02 in USA and Europe where they own all right...

April 25, 2016

Sage represents Luzitin (www.luzitin.pt) to develop a strategic alliance for its Redaporfin PDT combination therapy for solid tumours.

For decades Photodynamic Therapy (PDT) to treat cancer has held great promise due to its ability to selectively destroy tumours accessible to light along with the absence of harmful long term side effects often encountered...

February 4, 2015

​​

Isofol (www.isofolmedical.com), a clinical stage pharmaceutical company based in Gothenburg, Sweden, announces that following an internal review, it has launched a global program to identify one or more strategic partners for commercialization of its Modufolin® chemotherapy asset. The Sage Group (based in Europe, USA and Asia) has been appointed by Isof...

January 1, 2015

Graz, Austria, Cambridge UK, and Clinton NJ – January  2015 – CNSystems announces that following an internal strategic assessment, it has launched a global program to enter into  one or more strategic alliances for its non-invasive continuous hemodynamic monitoring systems. The Sage Group has been appointed by CNSystems to assist the company in this endea...

Please reload